Hyperfine, Inc.
- Open
- 1.49
- Day high
- 1.49
- Day low
- 1.32
- Prev close
- 1.47
- Volume
- 836K
- Mkt cap
- $136M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 4.0
- P/S
- 8.9
- Yield
- —
- Per share
- —
- ▼Insiders net selling -$20K over the last 3 months (0 open-market buys, 2 sales)
- 🏛Institutions accumulating (13F)
Hyperfine, Inc. (HYPR) is a Healthcare company listed on NASDAQ. The stock is up 96% over the past year. Over the trailing 3 months, insiders filed 0 open-market buys and 2 sales (SEC Form 4).
Hyperfine, Inc. (HYPR) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 2 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
HYPR earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 12, 2026 | $-0.09 | $-0.09 | +0.0% | $4M | +10.3% |
| Mar 18, 2026 | $-0.08 | $-0.06 | +21.6% | $5M | -0.1% |
| Nov 13, 2025 | $-0.10 | $-0.11 | -10.0% | $3M | -35.2% |
| Aug 13, 2025 | $-0.12 | $-0.12 | +0.0% | $3M | -10.1% |
| Mar 17, 2025 | $-0.16 | $-0.14 | +12.5% | $2M | +0.9% |
| Mar 21, 2024 | $-0.17 | $-0.15 | +11.8% | $3M | -27.6% |
| Nov 9, 2023 | $-0.15 | $-0.15 | +0.0% | $2M | -37.2% |
| Aug 14, 2023 | $-0.17 | $-0.15 | +11.8% | $3M | +5.7% |
| May 11, 2023 | $-0.16 | $-0.17 | -6.3% | $3M | +27.5% |
| Mar 21, 2023 | $-0.25 | $-0.19 | +24.0% | $1M | -43.0% |
| Nov 10, 2022 | $-0.26 | $-0.19 | +26.9% | $2M | +38.1% |
| Aug 10, 2022 | $-0.27 | $-0.33 | -22.2% | $2M | -23.4% |
HYPR insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 4, 2026 | Wolterman Dandirector | Grant | 52,600 | $1.49 |
| May 27, 2026 | TEISSEYRE THOMASofficer: Chief Operating Officer | Sell | 6,047 | $1.65 |
| May 27, 2026 | HALE BRETTofficer: CFO and CAO | Sell | 6,047 | $1.65 |
| May 22, 2026 | Fattori Ruth Adirector | Grant | 157,700 | $1.49 |
| May 22, 2026 | Dahldorf John Tdirector | Grant | 157,700 | $1.49 |
| May 22, 2026 | ROTHBERG JONATHAN Mdirector, 10 percent owner: | Grant | 157,700 | $1.49 |
| May 22, 2026 | Wolterman Dandirector | Grant | 157,700 | $1.49 |
| Apr 1, 2026 | Sainz Mariadirector, officer: President and CEO | Grant | 750,000 | — |
| Apr 1, 2026 | HALE BRETTofficer: CFO and CAO | Grant | 330,000 | — |
| Apr 1, 2026 | TEISSEYRE THOMASofficer: Chief Operating Officer | Grant | 330,000 | — |
| Mar 25, 2026 | HALE BRETTofficer: CFO and CAO | Sell | 24,188 | $1.21 |
| Mar 25, 2026 | TEISSEYRE THOMASofficer: Chief Operating Officer | Sell | 24,188 | $1.21 |
| Feb 17, 2026 | TEISSEYRE THOMASofficer: Chief Operating Officer | Sell | 821 | $1.11 |
| Nov 19, 2025 | TEISSEYRE THOMASofficer: Chief Operating Officer | Sell | 1,405 | $1.08 |
| Aug 18, 2025 | TEISSEYRE THOMASofficer: Chief Operating Officer | Sell | 1,151 | $1.33 |
Source: HYPR SEC Form 4 filings, latest Jun 4, 2026. For informational purposes only — not investment advice.
See the full HYPR insider & 13F page →Hyperfine, Inc. company profile
Overview
Hyperfine, Inc. (NASDAQ:HYPR) is a medical device company founded in 2014 and based in Guilford, Connecticut. The company went public in January 2021 through a SPAC merger. Hyperfine develops and commercializes portable magnetic resonance imaging (MRI) technology, with its flagship product being the Swoop Portable MR imaging system. The company represents a pioneering effort to make MRI technology more accessible by creating a portable, point-of-care solution that can be deployed in various healthcare settings beyond traditional hospital radiology departments.
Business
Hyperfine operates in the medical imaging industry, specifically focusing on magnetic resonance imaging (MRI) technology. Traditional MRI machines are large, expensive installations that require dedicated rooms with special shielding and infrastructure, typically costing millions of dollars and weighing several tons. These systems use powerful magnetic fields (usually 1.5 to 3.0 Tesla) to create detailed images of internal body structures. The company's core product is the Swoop Portable MR imaging system, which represents a fundamental reimagining of MRI technology. Unlike conventional MRI machines, the Swoop system is designed to be portable and can be wheeled directly to a patient's bedside. The system uses a lower magnetic field strength (0.064 Tesla) compared to traditional MRI scanners, but compensates through advanced artificial intelligence software to enhance image quality and clinical utility. The Swoop system addresses several key limitations of traditional MRI: it eliminates the need for patient transport to dedicated imaging suites, reduces the infrastructure requirements for MRI deployment, and enables point-of-care imaging in settings where traditional MRI would be impractical or impossible. The system is particularly targeted for neurological imaging applications, including stroke assessment, brain injury monitoring, and other neurocritical care scenarios. Hyperfine operates as a single business segment focused entirely on portable MRI technology, with revenue generated through direct sales of Swoop systems and associated software licenses. The company has been expanding its market reach through both direct sales in the United States and international distribution partnerships.
Competitive moat
Hyperfine's competitive moat appears moderately strong but not insurmountable. The company's primary advantages stem from being a first-mover in portable MRI technology with significant regulatory barriers to entry. The company has accumulated multiple FDA clearances for its AI-powered software systems, creating a regulatory moat that competitors must overcome. Additionally, Hyperfine has developed specialized expertise in low-field MRI optimization and AI-enhanced image processing that would be difficult for new entrants to replicate quickly. The company's clinical evidence generation through studies like ACTION PMR (stroke) and CARE PMR (Alzheimer's) creates additional defensive positioning by establishing clinical protocols and use cases specific to portable MRI. The installation base and customer relationships in specialized applications like neurocritical care also provide some switching cost advantages. However, the moat faces significant threats from well-capitalized incumbents in the medical imaging space. Major MRI manufacturers like GE Healthcare, Siemens Healthineers, and Philips have substantially greater resources and could develop competing portable solutions. These companies also have established relationships with hospital purchasing departments and existing service networks that could advantage their market entry. The fundamental physics of MRI are well-understood, and while Hyperfine's specific implementation is innovative, the core technology barriers are not prohibitively high for determined competitors. The company's small size relative to imaging giants also limits its ability to compete on price or invest in R&D at the scale of larger competitors. As the portable MRI market validates and grows, it becomes increasingly attractive for major players to enter, potentially commoditizing the technology over time.
Risks & safety
The margin of safety appears moderate to low given the company's current financial position and market dynamics. • Liquidity and Solvency: Strong cash position with $33.1 million in cash and short-term investments as of Q1 2025, providing runway through 2026. Current ratio of 6.07 indicates solid short-term liquidity. Minimal debt with debt-to-equity ratio near zero. • Cash Burn: Significant cash consumption with free cash flow of -$9.7 million in Q1 2025 and projected annual burn of $25-28 million. While burn rate has improved from prior years, the company remains pre-profitability with limited visibility on path to cash flow positive operations. • Valuation Metrics: Trading at 1.26x book value with negative earnings making P/E ratios less meaningful. Enterprise value to EBITDA is negative due to losses. Graham net-net ratio of 0.40 suggests the stock trades below liquidation value, potentially indicating deep value or fundamental concerns. • Other Considerations: Revenue growth has been positive but lumpy, with quarterly volatility typical of capital equipment sales. The small market cap of approximately $50 million creates liquidity risks and potential volatility. Regulatory dependence for new product approvals adds execution risk to growth projections.
Recent development
Over the past few years, Hyperfine has executed several key strategic initiatives to expand its market reach and improve its technology platform. The company has significantly enhanced its AI-powered software capabilities, receiving multiple FDA clearances for successive generations of imaging software, with the 9th generation cleared in 2024 and 10th generation expected in 2025. These software improvements aim to achieve image quality comparable to traditional 1.5 Tesla MRI systems while maintaining the portability advantage. A major strategic pivot has been the expansion beyond hospital-based sales into office-based neurology practices. The company has been working to obtain IAC (Intersocietal Accreditation Commission) accreditation standards for point-of-care MRI and expects to launch commercially in neurology offices by mid-2025. This represents a significant market expansion opportunity, as the company estimates over 2,000 potential neurology office locations compared to the more limited hospital market. International expansion has accelerated through a distributor model, with the company establishing 13 international distributors across Europe, the Middle East, and Asia. The company received CE marking for European sales and is pursuing regulatory approval in India, expected in the second half of 2025. This geographic diversification strategy aims to reduce dependence on the U.S. market while minimizing direct operational expenses. The company has also focused on clinical evidence generation through multiple studies including the ACTION PMR study for stroke applications and the CARE PMR study for Alzheimer's disease monitoring. These clinical programs are designed to establish evidence-based use cases that can drive adoption and potentially support reimbursement pathways. The Alzheimer's application, in particular, represents a potentially significant market opportunity as new treatments require regular monitoring for complications.
HYPR company profile · for informational purposes only — not investment advice.
Track HYPR with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free